Skip to Main Content
Centers for Medicare & Medicaid Services

View Public Comments for Draft Guidance for the Public, Industry, and CMS Staff Coverage with Evidence Development in the context of coverage decisions

Vance, Richard
I agree with the comment regarding lack of whole life evidence. All the evidence collections appear to be on cures and cost comparisons and perhaps this cure vs that but not much thought about after care cost and affect on the patient. Many conditions can be treated with "more expensive" options, meaning more expensive one time treatment and these more expensive options are denigrated because the investigation did not look to see that over the person's lifetime this up front cost reduces lifetime agony and expense. MUST assure that all comparative analyses looks at side effects of treatments and life long complications not just cure rates and such.